- Home
- GNFT vs DCTH Comparison
GNFT vs DCTH Comparison
Compare GNFT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- DCTH
- Stock Information
- Founded
- GNFT 1999
- DCTH 1988
- Country
- GNFT France
- DCTH United States
- Employees
- GNFT N/A
- DCTH N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- DCTH Medical/Dental Instruments
- Sector
- GNFT Health Care
- DCTH Health Care
- Exchange
- GNFT Nasdaq
- DCTH Nasdaq
- Market Cap
- GNFT 296.4M
- DCTH 379.8M
- IPO Year
- GNFT 2019
- DCTH N/A
- Fundamental
- Price
- GNFT $4.05
- DCTH $12.64
- Analyst Decision
- GNFT Strong Buy
- DCTH Strong Buy
- Analyst Count
- GNFT 1
- DCTH 4
- Target Price
- GNFT $13.00
- DCTH $21.50
- AVG Volume (30 Days)
- GNFT 7.6K
- DCTH 473.2K
- Earning Date
- GNFT 09-19-2024
- DCTH 11-08-2024
- Dividend Yield
- GNFT N/A
- DCTH N/A
- EPS Growth
- GNFT N/A
- DCTH N/A
- EPS
- GNFT 0.47
- DCTH N/A
- Revenue
- GNFT $86,225,222.00
- DCTH $22,644,000.00
- Revenue This Year
- GNFT $155.44
- DCTH $1,605.13
- Revenue Next Year
- GNFT N/A
- DCTH $111.67
- P/E Ratio
- GNFT $8.62
- DCTH N/A
- Revenue Growth
- GNFT 175.45
- DCTH 945.91
- 52 Week Low
- GNFT $3.12
- DCTH $2.60
- 52 Week High
- GNFT $6.42
- DCTH $12.88
- Technical
- Relative Strength Index (RSI)
- GNFT 25.70
- DCTH 73.89
- Support Level
- GNFT $4.17
- DCTH $9.33
- Resistance Level
- GNFT $4.41
- DCTH $10.04
- Average True Range (ATR)
- GNFT 0.11
- DCTH 0.61
- MACD
- GNFT -0.05
- DCTH 0.25
- Stochastic Oscillator
- GNFT 4.13
- DCTH 96.17
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.